160 related articles for article (PubMed ID: 31706158)
1. Rapid and sustained improvement in treatment-refractory depression through use of acute intravenous ketamine and concurrent transdermal selegiline: A case series.
Lu BY; Agapoff JR; Olson DJ; Williams SR; Roller A; Goebert D
J Affect Disord; 2020 Feb; 262():40-42. PubMed ID: 31706158
[TBL] [Abstract][Full Text] [Related]
2. Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients.
Bodkin JA; Amsterdam JD
Am J Psychiatry; 2002 Nov; 159(11):1869-75. PubMed ID: 12411221
[TBL] [Abstract][Full Text] [Related]
3. Repeated ketamine injections in synergy with antidepressants for treating refractory depression: A case showing 6-month improvement.
Wang M; Xiong Z; Su B; Wang L; Li Z; Yang Y; Fang J; Li Z
J Clin Pharm Ther; 2020 Feb; 45(1):199-203. PubMed ID: 31468568
[TBL] [Abstract][Full Text] [Related]
4. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
Thomas RK; Baker G; Lind J; Dursun S
J Psychopharmacol; 2018 Oct; 32(10):1110-1117. PubMed ID: 30182797
[TBL] [Abstract][Full Text] [Related]
5. New use for an old drug: oral ketamine for treatment-resistant depression.
Swiatek KM; Jordan K; Coffman J
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27489070
[TBL] [Abstract][Full Text] [Related]
6. Intravenous ketamine infusion for a patient with treatment-resistant major depression: a 10-month follow-up.
Kwon JH; Sim WS; Hong JP; Song IS; Lee JY
J Clin Pharm Ther; 2018 Aug; 43(4):581-583. PubMed ID: 29372569
[TBL] [Abstract][Full Text] [Related]
7. Repeated S-ketamine infusions in therapy resistant depression: a case series.
Segmiller F; Rüther T; Linhardt A; Padberg F; Berger M; Pogarell O; Möller HJ; Kohler C; Schüle C
J Clin Pharmacol; 2013 Sep; 53(9):996-8. PubMed ID: 23893490
[No Abstract] [Full Text] [Related]
8. [Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy].
Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
Psychiatr Pol; 2014; 48(1):49-58. PubMed ID: 24946434
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules.
Azzaro AJ; Ziemniak J; Kemper E; Campbell BJ; VanDenBerg C
J Clin Pharmacol; 2007 Oct; 47(10):1256-67. PubMed ID: 17715422
[TBL] [Abstract][Full Text] [Related]
10. Psychopharmacology column: why choose selegiline transdermal system for refractory depression?
Tobin M
Issues Ment Health Nurs; 2007 Feb; 28(2):223-8. PubMed ID: 17365170
[No Abstract] [Full Text] [Related]
11. The Antidepressant Effect of Repeat Dose Intravenous Ketamine Is Delayed by Concurrent Benzodiazepine Use.
Albott CS; Shiroma PR; Cullen KR; Johns B; Thuras P; Wels J; Lim KO
J Clin Psychiatry; 2017 Mar; 78(3):e308-e309. PubMed ID: 28394513
[No Abstract] [Full Text] [Related]
12. Use of Ketamine in Elderly Patients with Treatment-Resistant Depression.
Medeiros da Frota Ribeiro C; Riva-Posse P
Curr Psychiatry Rep; 2017 Nov; 19(12):107. PubMed ID: 29138992
[TBL] [Abstract][Full Text] [Related]
13. Can Quetiapine Prolong the Antidepressant Effect of Ketamine?: A 5-Year Follow-up Study.
Amiaz R; Saporta R; Noy A; Berkenstadt H; Weiser M
J Clin Psychopharmacol; 2021 Nov-Dec 01; 41(6):673-675. PubMed ID: 34668877
[TBL] [Abstract][Full Text] [Related]
14. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression.
De Gioannis A; De Leo D
Aust N Z J Psychiatry; 2014 Jul; 48(7):686. PubMed ID: 24452289
[No Abstract] [Full Text] [Related]
15. Metabolic Syndrome Rather Than Body Mass Index Is Associated With Treatment Response to Ketamine Infusions.
Dale RM; Bryant KA; Thompson NR
J Clin Psychopharmacol; 2020; 40(1):75-79. PubMed ID: 31834094
[TBL] [Abstract][Full Text] [Related]
16. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.
Mathew SJ; Wilkinson ST; Altinay M; Asghar-Ali A; Chang LC; Collins KA; Dale RM; Hu B; Krishnan K; Kellner CH; Malone DA; Murrough JW; Ostroff RB; Sanacora G; Shao M; Anand A
Contemp Clin Trials; 2019 Feb; 77():19-26. PubMed ID: 30572160
[TBL] [Abstract][Full Text] [Related]
17. Is Ketamine the Future Clozapine for Depression? A Case Series and Literature Review on Maintenance Ketamine in Treatment-resistant Depression With Suicidal Behavior.
Chan LF; Eu CL; Soh SY; Maniam T; Shahidii Kadir Z; Chong BTW; Loo JL; Sharip S; Wong VCW; Loo TH; Ng YP; Kahn DA
J Psychiatr Pract; 2018 Jul; 24(4):279-291. PubMed ID: 30427812
[TBL] [Abstract][Full Text] [Related]
18. Ninety-six hour ketamine infusion with co-administered clonidine for treatment-resistant depression: A pilot randomised controlled trial.
Lenze EJ; Farber NB; Kharasch E; Schweiger J; Yingling M; Olney J; Newcomer JW
World J Biol Psychiatry; 2016 Apr; 17(3):230-8. PubMed ID: 26919405
[TBL] [Abstract][Full Text] [Related]
19. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study.
Hartberg J; Garrett-Walcott S; De Gioannis A
Psychopharmacology (Berl); 2018 Feb; 235(2):393-398. PubMed ID: 29151192
[TBL] [Abstract][Full Text] [Related]
20. Transdermal selegiline in patients receiving electroconvulsive therapy.
Horn PJ; Reti I; Jayaram G
Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
